PMID- 33117018
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1179-2728 (Print)
IS  - 1179-2728 (Electronic)
IS  - 1179-2728 (Linking)
VI  - 11
DP  - 2020
TI  - Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung 
      Cancer.
PG  - 105-111
LID - 10.2147/LCTT.S270283 [doi]
AB  - PURPOSE: Surgery is the standard treatment for early-stage non-small cell lung 
      cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, 
      some patients are inoperable or refuse to undergo surgery. To explore whether 
      proton beam therapy (PBT) can be an alternative to surgical resection in these 
      patients, this study aimed to examine the retrospective treatment outcomes of 
      patients with GGO-type lung cancer who underwent PBT. PATIENTS AND METHODS: 
      Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton 
      Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 
      2015 were included. Patients were treated with a total dose of 66 GyE delivered 
      in 10 fractions. Survival curves were calculated using the Kaplan-Meier method, 
      and treatment-related adverse events (AEs) were assessed. RESULTS: A total of 48 
      patients (median age: 70.9 +/- 9.2 years; men: 54.2%) were analyzed, among whom 53 
      tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% 
      confidence interval [CI], 79.3-96.8%), the 3-year disease-free survival rate was 
      85.4% (95% CI: 71.8-92.8%), and the 3-year local control rate among 53 tumors was 
      92.5% (95% CI: 81.1-97.1%). During the 3-year follow-up period, 4 patients died, 
      and 3 survived despite recurrence or metastasis. Common AEs were radiation 
      pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the 
      patients developed grade >/=3 treatment-related AEs. CONCLUSION: The results of 
      this study suggest that PBT may be a promising alternative for patients with 
      GGO-type lung cancer when surgical resection is not feasible, with excellent 
      survival outcomes and tolerable treatment-related AEs.
CI  - (c) 2020 Nagata et al.
FAU - Nagata, Ichiro
AU  - Nagata I
AD  - Medipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan.
AD  - Department of Radiology, Graduate School of Medical and Dental Sciences, 
      Kagoshima University, Kagoshima, Japan.
FAU - Ogino, Takashi
AU  - Ogino T
AD  - Medipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan.
FAU - Arimura, Takeshi
AU  - Arimura T
AUID- ORCID: 0000-0002-8512-1316
AD  - Medipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan.
FAU - Yoshiura, Takashi
AU  - Yoshiura T
AUID- ORCID: 0000-0003-2918-4336
AD  - Department of Radiology, Graduate School of Medical and Dental Sciences, 
      Kagoshima University, Kagoshima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201009
PL  - New Zealand
TA  - Lung Cancer (Auckl)
JT  - Lung Cancer (Auckland, N.Z.)
JID - 101632521
PMC - PMC7553652
OTO - NOTNLM
OT  - Japan
OT  - adenocarcinoma
OT  - carcinoma
OT  - ground-glass opacity
OT  - non-small-cell lung
OT  - proton therapy
COIS- The authors declare that they have neither conflict of interest nor financial 
      support.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
PMCR- 2020/10/09
CRDT- 2020/10/29 05:50
PHST- 2020/07/04 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/29 05:50 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
PHST- 2020/10/09 00:00 [pmc-release]
AID - 270283 [pii]
AID - 10.2147/LCTT.S270283 [doi]
PST - epublish
SO  - Lung Cancer (Auckl). 2020 Oct 9;11:105-111. doi: 10.2147/LCTT.S270283. 
      eCollection 2020.